Together, the novel PP2A activators and pharmaceutically druggable approach in the current study target MYCN degradation, leading to a significant reduction in overall cell viability, proliferation, and migratory potential and a reduction in tumor volume in vivo. Here, MYCN is linked to neoplasm.